drugset / Trial / NCT04903509
A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide
RandomizedParallel-groupSingle-blindTreatment
Summary
The main objective of this trial is to investigate safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of BI 1820237 alone or together with a single low dose of liraglutide in male subjects with overweight/obesity (otherwise healthy) following subcutaneous administration of single rising doses.
Timeline
- Start
- 2021-06-08
- Primary completion
- 2022-08-26
- Completion
- 2022-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 1820237 | Unknown | — | Subcutaneous |
| Subject | Liraglutide | Peptide | — | Subcutaneous |
| Background | Acetaminophen | Small molecule | — | — |
Indications
No indication recorded.